Pharmaron

AsiaMap2

FiercePharmaAsia: Takeda, Valeant and more

In this week's FiercePharmaAsia wrap-up, Takeda has offered $5.2 billion to buy Ariad and made a $125 deal with Maverick on T-cell therapy R&D, Valeant sold Dendreon to a Chinese company for $820 million, and more.